searchAnastrozoleSystematic (IUPAC) name2-[3-(1-cyano-1-methyl-ethyl)- 5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- 2-methyl- propanenitrileIdentifiersCAS number 120511-73-1ATC code L02BG03PubChem 2187DrugBank APRD00016Chemical dataFormula C17H19N5Mol. mass 293.366 g/molSMILES eMolecules & proact study of arimidex dataBioavailability.

5 years the group that received anastrozole had significantly better proact study of arimidex results than the tamoxifen group. The trial suggested that anastrozole is proact study of arimidex preferred medical therapy proact study of arimidex postmenopausal women with localized breast cancer who received either anastrozole, tamoxifen, or both.[1] After more than 5 years proact study of arimidex group that received anastrozole had significantly better clinical results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized breast cancer that is estrogen receptor modulator: Afimoxifene, Bazedoxifene, Clomifene, Fulvestrant, Lasofoxifene, Raloxifene, Tamoxifen, ToremifeneAromatase inhibitor: Aminogluthetimide, Anastrozole, Exemestane, Formestane, Letrozole, VorozoleGonadotropins:(FSHR/LHCGR) ovulation stim.: Clomifene, UrofollitropinAntigonadotropins: Danazol, GestrinoneGnRH:(receptor) agonist: Buserelin, Goserelin, Histrelin, Leuprorelin, Nafarelin, proact study of arimidex Abarelix, Cetrorelix, Ganirelix.

(primarily G03, also L02, H01C) - human endogenous in CAPSProgestogens:(receptor) PROGESTERONE,Dienogest.